Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.02, read 2026-10-25
Ethical passes the values gate
Price127.64 USD
Fair value175.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Accumulation123.32+3.5% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown123.32+3.5% to today Markup gives way to Markdown
2026-07-02Read Markup128.40-0.6% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Covista Inc. holds its Accumulation at $127.64. Consolidating, no directional conviction, held for 33 days.
As held on the ledger · 2026-10-20
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 33 days
Price at the screen
$127.64
Valuation
17.04 trailing · 12.76 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.65
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.12%
Below 33%
Interest-bearing debt is just 28.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
12.56%
Below 49%
Money owed to the company is 12.6% of assets, under the 49% limit.
Pass
Revenue purity
0.46%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Covista clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-25. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CVSA's ethical verdict changes
Today CVSA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-20 screen. The gold marker is the market price at the same screen. A 37.1% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +25% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-20 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
When nurses chase degrees the cash flows slow
Covista turns healthcare training into steady revenue across US campuses and a handful of Caribbean sites. The three segments deliver degrees that keep nurses and vets qualified, yet the top line is expanding only 4 percent a year. At a forward multiple of 13.3 times, the shares sit below our fair value, but nothing in the numbers or the unknown moat suggests the discount will close quickly.
The business passes our ethical screen and shows an 18 percent return on equity with 12 percent margins. Those figures are respectable for consumer defensive education, yet revenue growth remains modest and four analysts offer no consensus rating. The gap between price and value looks wide on paper, but the lack of acceleration keeps any opportunity rating at none.
Low single-digit expansion in a regulated field brings its own limits. Currency or policy shifts in the Caribbean operations could trim margins, while slower enrolment would leave the multiple looking less attractive than it does today. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CVSA trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Accumulation$127.64+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$127.64+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$127.64+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$127.64+0.3%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$127.24+3.2%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156.
2026-10-02Markdown · changed$123.32-12.5%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156.
2026-08-26Markup$140.98+19.5%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156.
2026-07-25Markup$118.00-8.1%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 8.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156.
2026-07-18Markup$128.40+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (4 analysts) rates it none, with a mean price target of $156.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.